Relatlimab
Lymphocyte Activation Gene-3 Blocker — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: BMS-986016, BMS986016, ONO-4482, opdualag, relatlimab-rmbw
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Relatlimab is a drug in the Lymphocyte Activation Gene-3 Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2022. Its mechanism of action is classified as Lymphocyte Activation Gene-3 Antagonists. DrugCentral lists 1 molecular target, including LAG3. Recorded indications include Advanced melanoma with tumour cell PD-L1 expression below 1% and Unresectable or metastatic melanoma.
- Drug class: Lymphocyte Activation Gene-3 Blocker.
- Mechanism of action: Lymphocyte Activation Gene-3 Antagonists.
- Molecular targets: LAG3 (1 listed in DrugCentral).
- Indications: Advanced melanoma with tumour cell PD-L1 expression below 1% and Unresectable or metastatic melanoma.
- ATC code: L01FY02 (Combinations of monoclonal antibodies and antibody drug conjugates).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Advanced melanoma with tumour cell PD-L1 expression below 1%
- Unresectable or metastatic melanoma
Mechanism & targets
| Mechanism of action (MoA) | Lymphocyte Activation Gene-3 Antagonists |
|---|---|
| Established pharmacologic class | Lymphocyte Activation Gene-3 Blocker |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Lymphocyte activation gene 3 protein | LAG3 | antagonist | Kd 9.92 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2022-09-15 | EMA | — | BRISTOL-MYERS SQUIBB PHARMA EEIG | |
| 2022-03-18 | FDA | — | BRISTOL MYERS SQUIBB | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FY02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Combinations of monoclonal antibodies and antibody drug conjugates |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1673516-98-7 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Relatlimab used for?
DrugCentral lists the following indications for Relatlimab: Advanced melanoma with tumour cell PD-L1 expression below 1% and Unresectable or metastatic melanoma.
How does Relatlimab work?
Relatlimab is classified as Lymphocyte Activation Gene-3 Antagonists; its molecular targets in DrugCentral include LAG3 (antagonist).
When was Relatlimab first approved?
Relatlimab was first approved by the FDA in 2022.
What drug class does Relatlimab belong to?
Relatlimab is in the Lymphocyte Activation Gene-3 Blocker class.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5514 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3990044 — compound record and bioactivity
- DrugBank DB14851 — drug record
- FDA UNII AF75XOF6W3 — substance identity
- DailyMed: FDA labels for Relatlimab — current prescribing information (label search)
- UniProt P18627 (LAG3) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.